Short Interest in Ainos, Inc. (NASDAQ:AIMD) Expands By 289.3%

Ainos, Inc. (NASDAQ:AIMD) saw a large increase in short interest in May. As of May 29th, there was short interest totaling 91,823 shares, an increase of 289.3% from the May 14th total of 23,588 shares. Based on an average daily volume of 2,248,715 shares, the short-interest ratio is presently 0.0 days. Approximately 1.2% of the shares of the stock are short sold.

Insiders Place Their Bets

In other news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $2.36, for a total value of $96,760.00. Following the transaction, the insider owned 948,925 shares of the company’s stock, valued at approximately $2,239,463. The trade was a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ting-Chuan Lee sold 109,988 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total transaction of $208,977.20. Following the transaction, the director owned 807,417 shares of the company’s stock, valued at approximately $1,534,092.30. This represents a 11.99% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders acquired 7,800 shares of company stock worth $15,946 and sold 179,788 shares worth $359,247. 9.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ainos

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AIMD. Mariner LLC bought a new stake in shares of Ainos in the 4th quarter valued at approximately $37,000. Two Sigma Investments LP bought a new position in shares of Ainos during the 3rd quarter valued at approximately $80,000. DRW Securities LLC raised its holdings in Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after buying an additional 48,439 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Ainos Price Performance

Shares of NASDAQ:AIMD traded down $0.01 on Thursday, reaching $1.88. The company’s stock had a trading volume of 1,249 shares, compared to its average volume of 552,587. Ainos has a 52-week low of $1.26 and a 52-week high of $4.50. The company has a market cap of $16.03 million, a P/E ratio of -0.65 and a beta of 2.41. The company has a 50-day simple moving average of $1.82 and a 200 day simple moving average of $1.81. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.50 and a current ratio of 0.55.

Ainos (NASDAQ:AIMD) last announced its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.